Ketamine for depression: all studies (page 27)

Combining Intranasal Esketamine and Electroconvulsive Therapy in Severe Treatment‑Resistant Depression: A Case Series.

The Journal of ECT January 29, 2026 Sergi López-rodríguez, Aida De Arriba-Arnau, José Manuel Menchón et al. 1 citation

This case series describes the combined use of electroconvulsive therapy (ECT) and intranasal esketamine (ESK)-2 rapidly acting, evidence-based options for treatment-resistant depression (TRD). Each can leave residual symptoms or early relapse. Whether concurrent use confers more durable benefit remains unclear. We followed 4 adults (50 to 72 y) with severe TRD who had shown partial or waning...

DOI: 10.1097/yct.0000000000001233 Full text Esketamine Treatment-resistant depression Case series Combination therapy +2

Ketamine in the treatment of bipolar depression

Brazilian Journal of Health Review January 28, 2026 Juliana Chies Galvan, Marina Chies Galvan, Rafael Moreno Ferro de Araújo

Bipolar depression is the most prevalent state throughout the life of the bipolar patient, even so, few studies have focused on the treatment of depression in this population. Between the available medications approved for treatment of bipolar depression, ketamine is an option that must be considered. The purpose of this paper was to review the scientific evidence on the efficacy of using...

DOI: 10.34119/bjhrv9n1-120

Modulating tonic NMDA receptor currents: mechanistic insights into ketamine, esketamine, and dextromethorphan for major depressive disorder and implications for the discovery and development of investigational agents.

Expert Opinion on Therapeutic Targets January 28, 2026 Gia Han Le, Roger S McIntyre 1 citation

Up to 50% of adults with major depressive disorder (MDD) fail to achieve remission after two or more monoaminergic antidepressants and meet criteria for treatment-resistant depression (TRD). Low-dose intravenous ketamine, intranasal esketamine, and oral dextromethorphan represent the first glutamatergic treatments to exhibit rapid and robust efficacy in persons with TRD, yet their precise...

DOI: 10.1080/14728222.2026.2619757 Full text Treatment-resistant depression Esketamine Nmda receptor subunits Antidepressant mechanisms +2

Systematic review and meta-analysis of intranasal esketamine for treatment-resistant depression: Evidence from real-world studies.

Journal of Affective Disorders January 28, 2026 Clara De Oliveira Lapa, Thiago Viola, Rodrigo Delfino et al. 3 citations

Intranasal esketamine has demonstrated efficacy and safety for treatment-resistant depression in randomized controlled trials, however the generalizability of these findings to clinical practice remains unclear. This systematic review and meta-analysis aimed to synthesize real-world evidence of intranasal esketamine in patients with treatment-resistant depression. A systematic search was...

DOI: 10.1016/j.jad.2026.121257 Full text Esketamine Treatment-resistant depression Intranasal Meta-analysis +2

PSILOCYBIN IN PSYCHIATRIC PRACTICE AND PSYCHEDELIC-ASSISTED THERAPY FOR TREATMENT-RESISTANT DEPRESSION

International Journal of Innovative Technologies in Social Science January 28, 2026 Łukasz Deska, Cezary Kosmecki, Dawid Głaz et al.

This manuscript comprehensively reviews psilocybin-assisted therapy for major depressive disorder and treatment-resistant depression. It aims to synthesize current understanding regarding its mechanisms, efficacy, safety, costs, and accessibility, comparing it with conventional antidepressant and ketamine treatments. The methodology involved a narrative synthesis of academic literature, drawing...

DOI: 10.31435/ijitss.1(49).2026.4711 Psilocybin Major depressive disorder Treatment-resistant depression Ketamine +9

Astroglia and depression: A Gliocentric perspective from rodent models to therapeutic insights.

Progress in neuro-psychopharmacology & biological psychiatry January 27, 2026 Rhea Subba, Surendar Ellappan, Sugato Banerjee et al.

Major depressive disorder (MDD) is a debilitating neuropsychiatric condition that affects individuals worldwide. While neuronal deficits have long been recognized in depression pathogenesis, astroglia are increasingly gaining attention. Astroglia are essential for maintaining brain homeostasis, and regulate neurotransmission, neuroinflammation, and metabolic processes that are disrupted in MDD....

DOI: 10.1016/j.pnpbp.2026.111627 Full text Depression Ketamine Major depressive disorder Antidepressants +4

Serial ketamine infusions not effective as adjunctive care for depression

The Brown University Psychopharmacology Update January 24, 2026

Up to eight infusions of ketamine were not more effective than a psychoactive placebo in reducing depressive symptoms in patients receiving inpatient treatment for depression, a randomized trial has found. Patients receiving ketamine also showed no improvement relative to those receiving midazolam on measures of cognition and quality of life. Study results were published online Oct. 22, 2025 in...

DOI: 10.1002/pu.31401 Ketamine Depression economics Placebo Midazolam +6

Long-term effectiveness and side-effects of intranasal esketamine in treatment-resistant depression: real-world, single-arm study of over 100 sessions.

BJPsych Open January 23, 2026 Nawfel Ayad, Karim Abdel Aziz, Samer Makhoul et al. 2 citations

Treatment-resistant depression (TRD) poses a significant clinical challenge, with limited evidence guiding long-term pharmacological strategies. Esketamine, a glutamatergic modulator, has demonstrated short-term efficacy in TRD, but data on its extended use in real-world settings remains scarce. This study aimed to evaluate the long-term effectiveness and side-effects of intranasal esketamine...

DOI: 10.1192/bjo.2025.10950 Full text Treatment-resistant depression Esketamine Long-term effectiveness Maintenance therapy +1

Time matters for metas: a systematic review and meta-analysis of ect vs ketamine for depression incorporating time.

Translational Psychiatry January 23, 2026 Stevan Nikolin, Clara Massaneda-Tuneu, Louise Brettell et al. 1 citation

Comparing treatments for severe and medication-resistant depression is essential for guiding clinical decision-making. In this meta-analysis, we investigate the efficacy of electroconvulsive therapy (ECT) compared to ketamine for the treatment of major depressive disorder (MDD) and address the discrepant results of prior meta-analyses. We systematically searched PubMED (MEDLINE), Embase, and...

DOI: 10.1038/s41398-026-03806-z Full text

Symptom trajectories and clinical outcomes of intravenous ketamine in treatment-resistant depression: A real-world study using group-based trajectory modeling.

Journal of Affective Disorders January 23, 2026 Reinhard Janssen-Aguilar, Jithin Joseph, Huda Al-Shamali et al.

Intravenous (IV) ketamine is an emerging intervention for treatment-resistant depression (TRD), yet the temporal dynamics of response and the optimal number of infusions remain unclear, particularly in real-world clinical populations with psychiatric comorbidities. We conducted a retrospective chart review of 209 adults with TRD treated with IV ketamine at an interventional psychiatry program....

DOI: 10.1016/j.jad.2026.121230 Full text Anxiety Treatment-resistant depression Iv ketamine Real-world evidence +1

Research